These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Monitoring patients on methotrexate: hepatic fibrosis not seen in patients with normal serum assays of aminoterminal peptide of type III procollagen. Maurice PD, Maddox AJ, Green CA, Tatnall F, Schofield JK, Stott DJ. Br J Dermatol; 2005 Mar; 152(3):451-8. PubMed ID: 15787813 [Abstract] [Full Text] [Related]
3. Comment on: Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy. Boffa MJ, Smith A, Chalmers RJ. Rheumatology (Oxford); 2009 Nov; 48(11):1464; author reply 1465. PubMed ID: 19671697 [No Abstract] [Full Text] [Related]
4. Methotrexate and liver function: a study of 13 psoriasis cases treated with different cumulative dosages. Carneiro SC, Cássia FF, Lamy F, Chagas VL, Ramos-e-Silva M. J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):25-9. PubMed ID: 18181969 [Abstract] [Full Text] [Related]
5. The value of dynamic hepatic scintigraphy and serum aminoterminal propeptide of type III procollagen for early detection of methotrexate-induced hepatic damage in psoriasis patients. vanDooren-Greebe RJ, Kuijpers AL, Buijs WC, Kniest PH, Corstens FH, Nagengast FM, de Boo T, Willems JL, Duller P, van de Kerkhof PC. Br J Dermatol; 1996 Mar; 134(3):481-7. PubMed ID: 8731673 [Abstract] [Full Text] [Related]
8. Liver biopsies from psoriatics related to methotrexate therapy. 2. Findings before and after methotexate therapy in 88 patients. A blind study. Nyfors A, Poulsen H. Acta Pathol Microbiol Scand A; 1976 May; 84(3):262-70. PubMed ID: 1274591 [Abstract] [Full Text] [Related]
11. The value of amino-terminal propeptide of type III procollagen in routine screening for methotrexate-induced liver fibrosis: a 10-year follow-up. Zachariae H, Heickendorff L, Søgaard H. Br J Dermatol; 2001 Jan; 144(1):100-3. PubMed ID: 11167689 [Abstract] [Full Text] [Related]
15. Psoriatic arthritis: clinical response and side effects to methotrexate therapy. Espinoza LR, Zakraoui L, Espinoza CG, Gutiérrez F, Jara LJ, Silveira LH, Cuéllar ML, Martínez-Osuna P. J Rheumatol; 1992 Jun; 19(6):872-7. PubMed ID: 1404123 [Abstract] [Full Text] [Related]
16. Drug use and toxicity in psoriatic disease: focus on methotrexate. Taylor WJ, Korendowych E, Nash P, Helliwell PS, Choy E, Krueger GG, Soriano ER, McHugh NJ, Rosen CF. J Rheumatol; 2008 Jul; 35(7):1454-7. PubMed ID: 18609744 [Abstract] [Full Text] [Related]